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Introduction 
Over the past decade, there has been a change in the clinical investigation and management of 
men attending sexual health services in the UK. Previously, all men, regardless of symptoms, 
underwent urethral smears, a process by which a sample is taken from inside the urethra and 
Gram stained for examination by light microscopy (1). This allowed for the immediate 
diagnosis of two conditions: presumptive gonorrhoea and non-gonococcal urethritis 
(inflammation of the urethra in the absence of gonorrhoea). Men with either of these 
conditions, and their sexual partners, were then offered immediate treatment with appropriate 
antibiotics whilst waiting several days for more definitive results.  
With the widespread use of sensitive and specific non-invasive urine testing for chlamydia 
and gonorrhoea, and in order to streamline services in line with emerging evidence that it is 
not needed, guidelines now recommend only performing urethral microscopy in symptomatic 
men (1). A consequence of this change in practice is that asymptomatic men with urethritis, 
caused by neither chlamydia nor gonorrhoea (known as non-chlamydial, non-gonococcal 
urethritis or NCNGU), no longer receive empirical antimicrobial therapy. Their sexual 
partners are also left untreated. However, at the time of the most recent national audit (1), a 
small number of clinics continued to provide routine urethral microscopy to asymptomatic 
men, contrary to the guidelines.  
The potential impact of this change in practice on costs and patients outcomes is not clear and 
has not yet been explored in any depth. Asymptomatic urethritis has many causes, both 
infectious and non-infectious (1). Notably, Mycoplasma genitalium is present in 8-10% of 
men with asymptomatic urethritis (1) and is associated with both cervicitis and pelvic 
inflammatory disease in women (2). There is limited access to testing for M. genitalium in the 
UK and few men are tested for this organism. Therefore, whereas previously, men with 
asymptomatic urethritis secondary to M. genitalium and their partners may have received 
successful treatment as part of empirical therapy for urethritis, this is no longer the case.   
The focus of this study is on the potential cost implications of this change in clinical practice 
assuming that some men with asymptomatic NCNGU have M. genitalium, which can have 
adverse and costly reproductive health outcomes in their female sexual partners. Specifically, 
the objective of this economic evaluation is to determine whether the screening landscape at 
the time of the last national audit, in which a small number of clinics continued to perform 
routine microscopy in asymptomatic men is a cost-effective approach to diagnosing and 
treating asymptomatic NCNGU compared to the national guideline recommending not 
performing microscopy for this patient group. While it is acknowledged that there may be 
other causes of asymptomatic NCNCU other M. genitalium, there is little robust evidence 
that some of these may lead to important potential consequences. A previous study by 
Saunders et al. (2011) (3) found a paucity of high quality evidence that asymptomatic 
NCNGU is associated with significant consequences for men or their sexual partners. Thus, 
this study only considers cases caused by M. genitalium.  
Methods 
In order to estimate the impact of testing and treatment on the future transmission of possible 
significant pathogens responsible for asymptomatic NCNGU it is necessary to use an 
appropriate modelling approach for infectious diseases which can describe the transmission 
of M genitalium between individuals, namely a transmission dynamic model (TDM) (4, 5). In 
this study a TDM describing the transmission of M genitalium in the population of 16-30 year 
olds in England was constructed in order to examine changes in the use of urethral 
microscopy in asymptomatic men in genitourinary medicine (GUM) clinics. Here, the model 
output provides a hypothetical model state for asymptomatic patients which are defined here 
as those that do not have any symptoms associated with M. genitalium but who may present 
seek care following partner notification or who may spontaneously seek screening. This 
economic evaluation uses outputs from this model, along with secondary data describing 
resource use and takes the form of a cost-effectiveness analysis carried out from a health care 
provider perspective, with costs valued at 2014/2015 UK prices. 
Model structure 
The output used in this economic analysis is taken from a TDM which has been described in 
full elsewhere (6). In brief, this is a compartmental transmission model of the natural history 
of M genitalium, its diagnosis, and treatment levels, and thus only M genitalium was 
considered in this cost-effectiveness analysis. Heterogeneous sexual behaviour is described in 
the model which was parameterised by behaviour data from a number of key UK surveys, 
national surveillance data, and with the natural history of NCNGU being informed from data 
in the literature. The model describes the incidence and prevalence of symptomatic and 
asymptomatic infection, PID, care-seeking behaviour due to symptoms, partner notification, 
and the possibility of treatment failure. The uncertainty of the parameters in the model was 
also factored into the model parameterisation.  
The time horizon for the economic analysis is 20 years, although this is subject to sensitivity 
analysis. It was felt that a time horizon longer than this would not be appropriate due to the 
inevitable changes to testing technology and approaches to offering STI screening to the 
population in the future. A discount rate of 3.5% was applied to costs and outcomes in 
accordance with NICE guidelines (7). 
All settings where sexual health services are provided were initially considered for inclusion 
in this analysis. However, guidelines detailing the specific pathways and resources used at 
different sexual health service settings were sparse with the most reliable clinical data and 
cost data found in the literature being related to general practice (GP) and GUM settings, with 
GP consultations being considered due to the possibility of referral onwards to GUM services 
for further management. In this study the methodological focus is narrowed to the diagnosis 
and treatment of NCNGU in general practice and GUM clinics. 
Testing Pathways for Economic analysis 
Three different pathways are compared in terms of their resource use and costs, each 
representing alternative approaches to the testing and treatment of patients with 
asymptomatic NCNGU. These pathways represent: 1) the current recommended practice of 
not offering microscopy to asymptomatic men in GUM settings; 2) offering a small 
proportion (5%) of asymptomatic men microscopy (i.e. men attending a small number of 
GUM services) ; and 3) offering microscopy to all asymptomatic men attending all GUM 
services. These three pathways are referred to in this study as ‘Current Recommended 
Practice’, ‘5% Microscopy’, and ‘100% Microscopy’. 
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Initially, a patient can be either infected or non-infected with M. genitalium and either 
symptomatic or asymptomatic. The patient may attend either a GP or a GUM clinic for 
testing. For those patients that attend a GP setting, all patients (asymptomatic and 
symptomatic) are tested for chlamydia and gonorrhoea using nucleic acid amplification test 
(NAAT) but none are offered microscopy. From the GP setting a proportion of the patients 
are then referred to a GUM clinic for further investigation and management, for example 
those who are symptomatic or have more complex sexual health needs. 
In contrast, in the GUM setting the diagnostic pathway varies depending on which strategy is 
being considered and whether the patient presents with symptoms or not. For the ‘Current 
Recommended Practice’ strategy, microscopy is not offered to asymptomatic patients and 
these patients receive a NAAT test for chlamydia and gonorrhoea only. All asymptomatic 
patients in all locations in the ‘Current Recommended Practice’ scenario receive a NAAT 
chlamydia and gonorrhoea only. In the 5% Microscopy and ‘100% Microscopy’ scenarios, 
5% and 100% of male patients respectively at GUM clinics receive urethral smear 
microscopy. During the course of the consultation all symptomatic patients in a GUM setting 
receive partner notification and condoms with the aim of identifying individuals for whom 
testing and treatment may be appropriate. The testing pathways considered in this study are 
shown in Figure 1. 
In this analysis, treatment can be deemed either a success or failure. Successful treatment 
indicates that a patient is no longer infected with M. genitalium and cannot transmit infection 
to their sexual partners. Treatment failure indicates that there has been a failure of the drug 
treatment to clear M. genitalium. Female patients who fail treatment or who are not treated 
can develop PID, a proportion of which cases are treated. Untreated PID cases may go on to 
experience symptomatic PID, infertility, or experience an ectopic pregnancy.  
Model assumptions and parameterisation  
This cost-effectiveness analysis was parameterised through secondary sources which are 
described below. It was necessary to make some pragmatic clarifying assumptions in order to 
carry out the analysis, these are described in the Appendix.  
The model parameters used in this analysis are shown in Table 1.  
Parameter Value (range) Reference 
Proportion of times HIV test 
delivered alongside a NAAT 
test in a GUM setting 
83% (range=0.71-0.97) (8) 
Proportion of times syphilis 
tests delivered alongside a 
NAAT test in a GUM setting 
84% (range=0.72-0.97) (8) 
Proportion PID cases that give 
rise to ectopic pregnancy 
(99/1309) 7.6% (6.4-8.8%) (9, 10) Based on number trying 
to conceive after laparoscopy 
diagnosed PID case. Range 
calculated from a beta 
distribution taking values at 5% 
and 95% parameterised using 
method of moments (11) 
Proportion PID cases that give 
rise to infertility 
18% (15-21%) (9, 12) range calculated from a 
beta distribution taking values 
at 5% and 95% assuming 
standard error = mean/10 (11) 
Proportion of PID cases that are 
symptomatic 
56% (30%-89%) Value here from Posterior-mean 
of infectious disease model 
Treatment Failure Proportion 0.28 Posterior value from TDM 
Delay from PID to infertility / 
ectopic pregnancy manifest 
5 years (1-15years) Expert opinion – study team 
Table 1: Model parameters used in economic evaluation 
 
Resource use and costs  
The cost of partner notification was adjusted to 2014/15 prices using the pay and price index 
for Hospital & Community Health Services. Unit staff costs were obtained from Unit Costs 
of Health & Social Care (2015) (13). The unit costs of each resource used in this economic 
evaluation are described in the Appendix.  
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Outcomes 
The main outcome measure for this evaluation is the additional cost incurred per case of PID 
averted. The second outcome measure is the additional cost incurred per major outcome 
averted (MOA), where a major outcome is defined as a case of symptomatic PID, case of 
ectopic pregnancy, or a case of infertility. All major outcomes are reported for completeness. 
The results presented here use the incremental cost-effectiveness ratio (ICER), which is the 
difference in costs between two options divided by the difference in their effects (which are 
the outcome measures described above). 
Analysis 
The base case scenario uses the mean results of 215 parameter sets from the dynamic 
transmission model and applies resource costs to obtain the baseline deterministic results for 
each of the three testing scenarios. These deterministic results from the TDM are shown in 
the Appendix along with details of the sensitivity analysis. 
Results 
All results presented here are shown for a time horizon of 20 years with discounting unless 
otherwise stated. In all cases the costs are presented to the nearest thousand, and the 
outcomes to the nearest hundred. ICER values were calculated using the unrounded cost and 
outcome values with these then being rounded to the nearest 100.  
 Cost 
Cases of 
PID 
Major 
outcomes
* 
Symptomatic 
PID Infertility 
Ectopic 
Pregnancy 
No Microscopy £1,244,736,000 111,800 37,600 23,300 10,000 4,200 
5% Microscopy £1,249,986,000 111,500 37,500 23,200 10,000 4,200 
100% Microscopy £1,350,369,000 105,300 35,600 21,800 9,700 4,100 
Table 2: Baseline results for the three strategies for cases of PID and all the major outcomes 
considered in this study 
*
where major outcomes are symptomatic PID, infertility or ectopic pregnancy 
Outcomes 
As shown in Table 2, providing microscopy to 5% of asymptomatic men in a GUM setting 
has a positive impact on cases of PID. That is, the number of PID cases is lower for 5% 
Microscopy compared to No Microscopy. Likewise 5% Microscopy coverage also has a 
positive impact on reducing the number of major outcomes. In the case of the 100% 
Microscopy scenario, this has a greater impact on reducing cases of PID and major outcomes 
compared to either 5% or No Microscopy.  
Costs 
When only considering costs, it can be seen that the cost of 5% Microscopy coverage is 
greater than No Microscopy, while 100% Microscopy coverage is the most costly approach. 
This indicates that any savings that might have been made as a result of a reduction in major 
outcomes are insufficient to make 5% Microscopy or 100% Microscopy cost saving. 
  
Incremental Results  
 Discounted cost Cases of PID 
ICER  
(/PID averted) 
Major 
Outcomes 
ICER 
(/MOA) 
No Microscopy £1,244,736,000 111,800  37,600  
5% Microscopy £1,249,986,000 111,500 £15,700 37,500 £49,900 
100% Microscopy £1,350,369,000 105,300 £16,300 35,600 £51,900 
Table 3: Incremental cost per case of PID averted and cost per major outcome averted 
For the outcome of a case of PID averted the ICER values are shown in Table 3. It can be 
seen that 5% Microscopy is more effective than no microscopy and has an ICER of £15,700, 
meaning that an investment of £15,700 is required to avert one case of PID. For the outcome 
of MOA it can again be seen (Table 3) that 5% Microscopy is more effective than no 
microscopy, but in this case an investment of £49,900 is required to avert one major outcome. 
In the case of 100% Microscopy, an investment of £16,300 is required to avert one case of 
PID, and £51,900 to avert one major outcome compared to 5% Microscopy. 
Sensitivity Analysis 
The results of the sensitivity analysis are described in the Appendix. 
  
Discussion 
Principal Findings 
This economic evaluation utilized the output from a transmission dynamic model (TDM) to 
estimate whether providing limited microscopy coverage to asymptomatic men to test for 
NCNGU at a limited number of GUM services (as was the case at the time of the last national 
audit of practice (1)) is a cost-effective option compared to the recommended current practice 
of its complete withdrawal.  
This economic analysis was based on a principal outcome of cases of PID averted, and a 
secondary outcome of major outcome averted (MOA) (symptomatic PID, infertility, or 
ectopic pregnancy). The results at baseline indicate that performing urethral smear 
microscopy for approximately 5% of asymptomatic men attending GUM has an incremental 
cost of £15,700 per case of PID averted compared to no microscopy, meaning that this 
strategy invests approximately £15,700 to avoid one additional case of PID compared to a 
strategy of no routine microscopy screening where only symptomatic men are tested. 
Similarly 5% Microscopy coverage requires approximately £49,900 to avert one major 
outcome compared to a strategy of no routine microscopy screening where only symptomatic 
men are tested. Hypothetically, if recommended current practice were expanded to 
performing urethral smear microscopy for 100% of asymptomatic men attending GUM then 
this would have an additional cost of £16,300 per additional case of PID averted, and an 
additional £51,900 to avert an additional case of MOA compared to 5% Microscopy. These 
results also help to show that while conducting microscopy for 5% of asymptomatic men at 
GUM locations will avert PID and other major outcomes, at a population level it costs more 
to undertake the microscopy and associated patient management than it does to manage the 
adverse effects of not preventing the sequelae in a limited number of patients.  
Across all the sensitivity analysis undertaken, 5% microscopy coverage was never found to 
be cost saving but was always found to have a positive impact on reducing cases of PID and 
major adverse outcomes. Varying the outputs from the TDM provided a range of values for 
the outcomes in this study. For case of PID averted the ICER values ranged from £9,600-
£39,100, while for case of MOA the ICER values ranged from £30,500-£124,400. By varying 
the time horizon of the analysis it was found that shorter time horizons made the intervention 
less cost-effective.  
 
Strengths & Weaknesses of Study 
This study has utilised the output from a well parameterised dynamic model that describes the 
transmission of M. genitalium in the population of males and females in England aged 16-30 
years old. Uncertainty in this model has been considered through the use of multiple 
parameter sets, while the results from this economic evaluation have been subject to 
extensive sensitivity analysis. Inevitably this has led to the range of plausible values being 
obtained from the economic model being quite wide, although this does help to give 
confidence to the validity of the conclusions that might be drawn from this model. 
In this analysis only NCNGU due to M. genitalium has been considered in the analysis, and 
its scope has not been extended to other causes. There are some causes which are innocuous 
conditions that are not tested for, such as adenovirus which are not known to cause 
reproductive sequelae in women. Consequently had these non-serious causes been taken into 
account, then it is very likely that the testing strategies would have been even less cost-
effective than has been shown here. 
A weakness of this study is the inability to conduct joint probabilistic sensitivity analysis 
(PSA) for both the economic parameters and the parameters utilized in the transmission 
dynamic model. Although it was possible to conduct PSA for just the economic parameters 
while maintaining that output from the TDM at constant values, the results describing the 
probability of a strategy being below a specific acceptable threshold would be meaningless. 
Comparisons with existing studies 
To our knowledge this is the first economic analysis related to NCNGU in any setting, and 
thus comparisons with the results from similar economic studies are impossible. 
Meaning of study 
It is suggested that UK decision makers are unlikely to fund an intervention if it has an ICER 
value of £30,000 / quality adjusted life year (QALY) or more (14), meaning that the extra 
health gain of an intervention as measured in QALYs must not cost more than £30,000 per 
QALY gained. However, as this study analysed outcomes in terms of cases of PID and major 
outcomes averted and not in terms of cost per QALY, there are no accepted threshold values 
which can be used to assess whether providing limited microscopy coverage to asymptomatic 
men is acceptable or not. This means that if an intervention is more costly and more effective 
than its comparator, we have no indication of whether the extra effectiveness will be worth 
paying for. It is therefore necessary to link the results here to the acceptance threshold values 
for the QALY in order to draw conclusions from this economic analysis.  
Taking mean values from the transmission dynamic model, the ICER for a case of PID 
averted and MOA were £15,700 and £49,900 respectively for 5% microscopy compared to no 
microscopy. Using the outcome of case of PID averted as an example, and taking into 
consideration the maximum acceptance threshold of £30,000 / QALY used by the National 
Institute of Healthcare and Care Excellence (NICE) in England, for this ICER to be deemed 
cost-effective based on current accepted thresholds, a case of PID averted would have to 
result in a gain of 0.53 of a QALY. Alternatively, the implication is that having PID would 
have to be equivalent to losing more than 6 months of perfect health. Likewise for MOA this 
would have to be more than 1.67 QALYs, meaning that having a major outcome would have 
to be equivalent to losing more than 18 months of perfect health.  
Even allowing for patient suffering and particularly the stress of infertility, current evidence 
suggests that these outcomes are not valued so extremely. Smith (15) in a primary study 
based on a time trade off approach, asked respondents with a previous history of PID to value 
alternative conditions. The mean valuations for long term health states associated with PID 
were: ectopic pregnancy 0.79 (SD=0.34); pelvic pain 0.69 (SD=0.37); Infertility 0.76 
(SD=0.34). These values suggest that the mean QALY gain to avert a case of pelvic pain (the 
state with the reported greatest negative impact on QoL) that lasted one year would be 0.31 
QALYs. However as noted above for the results described here, for 5% microscopy coverage 
to be cost effective, a MOA must lead to a gain of more than 1 QALY, suggesting that the 
current practice of providing limited microscopy coverage for asymptomatic men is far from 
being cost-effective.  
Given the comparisons described above, it can therefore be concluded that the recommended 
practice of reserving urethral microscopy for symptomatic men and not testing asymptomatic 
men is a cost-effective strategy and reintroducing ad-hoc testing for asymptomatic men in 
GUM locations is unlikely to be cost-effective. Considering the results at baseline in this 
study, if ad-hoc microscopy testing for asymptomatic men were reintroduced into GUM 
locations then this would lead to over £5,000,000 (discounted) in costs over a 20 year period, 
which could then be better spent expanding testing and treatment regimens for different 
diseases which are more cost-effective. However the results shown in this study do very 
much represent the current situation in terms of testing for M. genitalium, indeed, as 
diagnostic technology moves forward, it is likely that routine screening for M. genitalium 
will become more viable in terms of its effectiveness at improving patient outcomes and cost-
effectiveness. 
Unanswered questions and future research 
One of the major issues related to any testing and diagnosis strategy is the impact of the 
testing pathway on patients. Patients may suffer from anxiety while waiting for the result of a 
test, or may incur societal costs as a result of having to take time off work to attend for 
testing. There are also issues specific to the context of sexually transmitted infections where 
patients may be worried about the stigma of attending for testing and the difficulties 
surrounding partner notification for NCNGU. In the testing and diagnosis context, future 
work should focus on these issues, in order to better quantify their impact on patients with the 
goal of including the impact of these issues in economic studies such as this in order to better 
describe the true impact of the complete testing pathway on patients. Furthermore, this study 
has not considered the possibility of targeting high risk asymptomatic males with a NAAT for 
M. genitalium, e.g. males that have a sexual partner with risk factor for STI, males that 
undertake high-risk sexual behaviour, or males that have had sexual contact with persons 
with an STI or PID. This could be considered in future work, since targeting these individuals 
is likely to have a positive impact on disease transmission and therefore cost-effectiveness. 
Finally, we recognise that our understanding of the urethral microbiome and the significance 
of micro-organisms found in the male urethra is incomplete. It may be that other organisms 
also cause male urethritis and are associated with adverse reproductive consequence in 
women. As information becomes available, future work can take this new knowledge and 
update our approach to provide more robust cost-effectiveness estimates. 
 
Key Messages 
 Current clinical recommendations for the UK are that urethral microscopy should not 
be offered to asymptomatic men attending genitourinary medicine clinics for 
diagnosis of NCNGU 
 Offering Microscopy at very low level of coverage where a small number of GUM 
services in England routinely offered asymptomatic men urethral microscopy for 
NCNGU is not cost-effective and wastes resources which could be put to better use 
elsewhere 
 Complete withdrawal of microscopy testing for asymptomatic men in a GUM setting 
could save over £5,000,000 (discounted) over a 20 year period 
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Appendix 1 
Model Assumptions 
All assumptions were confirmed and agreed with clinical experts within the team before the 
analysis was carried out. The following assumptions were made: 
 Symptomatic patients are index patients with symptoms due to their underlying 
infection 
 An HIV and syphilis blood test is administered 5% of the time in a GP setting (expert 
opinion) 
 All patients in all settings receive a NAAT test for Chlamydia and Gonorrhoea 
 A GP consultation takes 11.7 minutes which is the average for a surgery consultation 
(13) 
 All patients in a GUM setting are seen 50% by a doctor and 50% by a band 7 (clinical 
specialist) nurse (Expert opinion) 
 Partner notification is conducted with all symptomatic patients in a GUM setting by a 
band 7 nurse and this takes 12 minutes (16) 
 No formal partner notification is conducted in a GP setting, with just brief ‘words of 
advice’ to encourage sexual partners to attend for testing and treatment being given 
which was not considered in this economic analysis 
 Taking case history takes 5 minutes for asymptomatic patients in a GUM setting 
(Expert opinion – study team) 
 Taking case history takes 10 minutes for symptomatic patients in a GUM setting 
(Expert opinion – study team) 
 Examination of a female patient in a GUM setting takes 10 minutes (Expert opinion – 
study team) 
 Examination of a male patient in a GUM setting takes 5 minutes (Expert opinion – 
study team) 
 A single dose (1g) of azithromycin is given as treatment for NGNCU 
 For all microscopy tests implemented it takes 10 minutes for a lab technician to obtain 
and report the results of the microscopy test (Expert opinion – study team) 
 The treatment for PID considered in this study is intramuscular ceftriaxone 500mg 
single dose followed by oral Doxycycline 100 mg twice daily plus metronidazole 
400mg twice daily for 14 days (17) 
 All notified partners are assessed and presumptively treated in a GUM location and 
are asymptomatic (Expert opinion – study team) 
 The cost of PID does not include the cost of assisted reproduction 
 
Resource Use and Costs 
The ranges for the costs were taken by firstly describing the variation in the length of time of 
the procedures through the use of a gamma distribution with the mean = standard error and 
taking the values at the 5% and 95% points (with the minimum consultation time set to 2 
minutes). And then secondly where more than one member of staff is assumed to contribute 
to an examination the cheapest and more expensive members of staff would be assumed to 
conduct the examination for the low and upper values of the range respectively. Some costs 
are unit costs and as such have a fixed cost that does not vary. 
 
Resource Unit Cost Range Source 
NAAT nucleic acid amplification test - 
"NAAT” 
£9.27  £7.35 for a swab 2005 prices = cost of hands-on time + equipment and consumables cost per test [7] 
HIV test  £8.47  Rapid test kit £5-£11 (18) (mid-point 2014/15 prices) 
Syphilis test £2  EIA Assume £2  
Microscopy test (including staff costs) £7  NHS reference costs 2014-15 HRG DAPS07 Microscopy 
Lab Technician (10 minutes of staff time) to 
obtain and report results of microscopy test 
£3.33 £0.67-£10 
 
Clinical support worker nursing (community) £20 /hr (13) (Range 2min-30min) 
Staff time to give results for Microscopy at 
Genitourinary Medicine (5 minutes of staff 
time) 
£6.75 £2.70-£20.25 5 minutes with Nurse advanced (£81 / hour) (13) (Range 2min – 15min) 
Azithromycin – drug cost for treatment £6.44  BNF accessed 21st June 2016 250mg tablets 4-tab pack £6.44 
General Practice visit (excluding testing costs) £44 £7.50-£131.25 GP includes direct care staff costs (with qualification costs, £225/hr) Assume 11.7 min surgery consultation 
(13) (Range 2min-35min) 
Cost of Partner Notification in GUM setting –
administered to all symptomatic patients 
£16.2 £2.70-£48.60 12 minutes with Nurse Advanced (£81 / hour (13) (Range 2min-36min) 
Partner Notification leaflets + condoms given 
out during partner notification 
£1.00  Assumed cost 
Asymptomatic female at GUM clinic - Case 
history + Exam (13 minutes of staff time) 50% 
with Band 7 nurse and 50% with GP 
£27.30 £2.70-£111.15 Nurse advanced cost per hour in surgery excluding qualification costs (£81 / hour) '+ GP excluding direct 
care staff costs (without qualification costs) (£171 / hr patient contact) (13) (Range 2min – 53min) 
Symptomatic female at GUM clinic - Case 
history + Exam (18 minutes of staff time) 50% 
with Band 7 nurse and 50% with GP 
£37.80 
 
£1.35-£153.90 “” Range (2min-73min) 
Asymptomatic male at GUM clinic – Case 
history + Exam (10 minutes of staff time) 50% 
with Band 7 nurse and 50% with GP 
£21 
 
£2.70-£85.50 “” Range (2min-41min) 
Symptomatic male at GUM – Case history + 
Exam (15 minutes of staff time) 50% with Band 
7 nurse and 50% with GP 
£31.50 £2.70-£128.25 “” Range (2min-62min) 
Cost of treating PID  £14.52  Ceftriaxone 500mg single dose, (1g vial) £9.58; Doxycycline 100mg twice daily for 14 days 100mg 8-cap 
pack £0.55 x 4; and Metronidazole 400mg twice daily for 14 days, 21-tab pack £1.37 x 2 
Ectopic Pregnancy £436.48  MA18C medical termination of pregnancy – less than 14 weeks gestation, elective inpatient NHS ref costs 
14-15 
Infertility £587.02  £428 in 2003 (16) Using the hospital and community health services (HCHS) index to inflate to 2014 price 
2002/03 index = 213.7 2014/15 index = 293.1. One cycle of treatment assumed per case 
Table 2: Resource use and costs 
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Sensitivity Analysis 
Two scenarios were examined to assess the impact of increasing and decreasing the costs 
applied in the study as follows: 
 Minimize costs - All costs are set to a minimum by taking the lowest realistic length 
of time for all consultations in all settings (minimum 2 minutes). Where two staff 
members undertake a consultation at baseline, in this scenario only the lowest paid is 
assumed to carry out the consultation.  
 Maximize costs – All costs are set to a maximum by taking the highest realistic length 
of time for each consultation. Where two staff members undertake a consultation at 
baseline, the highest paid of the staff members is assumed to carry out the entire 
consultation.  
In addition, three further outputs from the transmission model were also analysed to assess 
their impact on the model results. These were median results (Median) from the 215 
parameter sets of the transmission dynamic model, and the upper (Upper) and lower (Lower) 
results from the 95% range of values. 
Further one-way sensitivity analysis of key parameters was also investigated, with particular 
attention paid to parameters that were estimated through expert opinion. In addition the time 
horizon was also varied to show its impact on conclusions drawn from the model. 
  
Appendix II 
 
Mean Output from the Transmission Model 
The following graphs provide a summary of the mean output from the transmission model 
which was utilized in this economic analysis at baseline for each of the two scenarios 
considered in this study.  
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Figure A1: Output from the transmission model used in the baseline economic analysis with 
variation in the testing strategy  
 
It can be seen from Figure A1 that increasing the coverage of microscopy leads to an increase 
in the annual number of consultations in both GP and GUM locations. Moreover this 
increasing coverage also has a positive impact on reducing the number of cases of PID 
averted, the number of cases of infertility, and the number of cases of ectopic pregnancy. It 
also lowers the number of true positive patients with NGNCU being treated, due to its impact 
on onward transmission.  
  
Appendix III 
Sensitivity Analysis -Results 
The two scenarios examined in this study consider the impact of reducing and increasing 
multiple cost parameters to see their cumulative impact on the results obtained from the 
model.  
Parameter ICER 
/PID averted 
ICER  
/MOA 
Maximize Costs £34,000 £108,500 
Minimize Costs £9,600 £30,500 
Table A1: Sensitivity analysis results for the alternative cost scenarios for No Microscopy vs. 
5% Microscopy 
 
As shown in Table A1, by varying the costs applied in the model it can be seen that for No 
Microscopy vs. 5% Microscopy the ICER for PID averted ranges from £9,600-£30,500 while 
the ICER for MOA ranges from £34,000-£108,500. 
 
Variations in Transmission Model Output 
The sensitivity analysis above has only considered uncertainty in the parameters used in the 
economic evaluation and has until now only adopted mean values from the infectious disease 
model. In order to examine how uncertainty in the output from the infectious disease model 
affects the conclusions drawn from the economic model, a further series of outputs from the 
infectious disease model were also considered, these being the median results obtained from 
the 215 parameter sets along with upper and lower limits informed by the 95% ranges. 
Dynamic transmission model 
output scenario 
ICER  
No Microscopy vs. 5% Microscopy 
Cost / Case of PID averted; Cost/ MOA 
Mean £15,700; £49,900 
Median £39,100; £124,400 
Upper £30,400; £95,400 
Lower £10,800; £34,600 
Table A2: ICER values for the outcomes of case of PID averted and major adverse event 
averted with variation in the infectious disease model output 
 
By examining that impact of various plausible outputs from the TDM (Table A2), it can be 
seen that the range of ICER values for No Microscopy vs. 5% Microscopy for the outcome 
measure of case of PID averted treated range from £10,800-£39,100 and for major outcome 
averted range from £34,600-£124,400. 
 
Time Horizon 
In order to investigate the impact of the time horizon on the model results, the results from a 
range of alternatives are considered here. Table A3 shows the impact of varying the time 
horizon on the cost, the number of PID cases averted, and MOA. It can be seen that in the 
short term limited microscopy is least cost effective, but the intervention becomes more cost-
effective the further the time horizon is extended into the future. 
  
  
Time 
Horizon 
 
Scenario 
Cost 
Cases of 
PID  
ICER (PID 
case 
averted) 
Major 
Outcomes 
ICER 
(/MOA) 
5 years No Microscopy £395,381,000 35,500  11,900  
5% Microscopy £397,087,000 35,400 £41,000 11,900 £146,600 
       
10 years No Microscopy £728,324,000 65,400  22,000  
5% Microscopy £731,433,000 65,300 £22,600 22,000 £76,800 
       
15 years No Microscopy £1,008,676,000 90,600  30,500  
5% Microscopy £1,012,950,000 90,400 £17,800 30,400 £57,900 
       
20 years No Microscopy £1,244,736,000 111,800  37,600  
5% Microscopy £1,249,986,000 111,500 £15,700 37,500 £49,900 
Table A3: Deterministic results for each of the outcomes considered in this study with 
variation in the time horizon 
 
One-way sensitivity Analysis 
The parameters, proportion of PID cases that are symptomatic and the delay from PID to 
infertility / ectopic pregnancy manifest were informed by expert opinion in this study, and as 
such it is necessary to examine their impact on the results from the model. Neither of these 
parameters had an impact on the ICER values for the main outcome measure used in this 
study, namely, cases of PID averted, but can impact on MOA. This is shown in the table A4.  
  
 Parameter ICER  
/PID averted 
ICER  
/MOA 
Delay from PID to Infertility / ectopic pregnancy 
1 years £15,600 £47,200 
2 £15,700 £47,900 
3 £15,700 £48,600 
5 (Baseline)  £15,700 £49,900 
10 £15,700 £52,900 
15 £15,700 £55,300 
Proportion of PID cases that are symptomatic
 
20% £15,700 £96,900 
40 £15,700 £63,600 
56 (Baseline) £15,700 £49,900 
60 £15,700 £47,400 
80 £15,700 £37,700 
100 £15,700 £31,300 
Table A4: Results from one-way sensitivity analysis for No Microscopy vs. 5% Microscopy 
It can be seen that varying these parameters has very little impact on the ICER values for the 
primary outcome measure of cost / case of PID averted. In the case of MOA, for the 
parameter estimated time to infertility / ectopic pregnancy manifest, as this is increased, 5% 
Microscopy becomes increasingly less cost-effective. For the proportion of PID cases that are 
symptomatic, increasing this value leads to the ICER values for MOA to decrease, thus 
making 5% Microscopy more cost-effective. 
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